Earnings Presentation 1st Quarter 2025 May 8th, 2025 Company Overview ACIC is a specialty underwriter of catastrophe exposed commercial property insurance. American Coastal Insurance Corp. (Nasdaq: ACIC) is the insurance holding company for American Coastal Insurance Company (AmCoastal), a Florida domiciled P&C carrier, and Skyway Underwriters (SKU), a managing general agency, along with other operating affiliates. AmCoastal is a balance sheet underwriter and has the #1 market share of commercial residentia ...

Monster Beverage (MNST) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Rodney Sacks - Co-CEO & Chairman Thomas Kelly - CFO Kaumil Gajrawala - Managing Director Hilton Schlosberg - Vice Chairman and Co-CEO Dara Mohsenian - Managing Director - US Beverage/Household Products Sectors Filippo Falorni - Director - Equity Research Kevin Grundy - Managing Director Conference Call Participants Bonnie Herzog - Analyst Operator Please note this event is being recorded. I would like now to turn the ...

The Trade Desk (TTD) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Chris Toth - Vice President, Investor Relations Jeff Green - Chairman, CEO & Founder Laura Schenkein - Chief Financial Officer Justin Patterson - Managing Director Matthew Swanson - Director - Equity Research Jessica Reif Ehrlich - Managing Director Mark Kelley - MD - Internet Conference Call Participants Shyam Patil - Analyst Vasily Karasyov - Founder & Senior Analyst Operator Greetings. Welcome to The Trade Desk First ...

Financial Data and Key Metrics Changes - Q1 revenue reached $616 million, representing a 25% year-over-year increase [45] - Adjusted EBITDA for the quarter was $208 million, reflecting a 34% margin [45] - Adjusted net income was $165 million, or $0.33 per fully diluted share [49] - Free cash flow was $230 million in Q1 [49] Business Line Data and Key Metrics Changes - CTV (Connected TV) remains the largest and fastest-growing advertising channel, representing a high 40s percentage share of the business [46] - Mobile accounted for a mid-30s percentage share of spend, while display represented a low double-digit share and audio around 5% [46] - The adoption of the Kokai platform accelerated, with about two-thirds of clients now using it, ahead of schedule [60] Market Data and Key Metrics Changes - North America represented approximately 88% of spend, while international markets accounted for about 12% [46] - International growth outpaced North America for the ninth consecutive quarter, driven by CTV [47] Company Strategy and Development Direction - The company aims to capture market share in a more competitive landscape, particularly in the open Internet space [19][40] - Innovations like OpenPath and the acquisition of Sincerra are expected to enhance supply chain efficiency and transparency [24][28] - The focus remains on maintaining independence and objectivity to differentiate from competitors like Google and Amazon [45][82] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to navigate macroeconomic uncertainties and continue to grow [51] - The outlook for Q2 anticipates revenue of at least $682 million, reflecting a 17% year-over-year growth [51] - The company is optimistic about the open Internet's prospects following recent antitrust rulings against Google [19][70] Other Important Information - The company has no debt and ended the quarter with approximately $1.7 billion in cash and short-term investments [49] - A significant share repurchase program was executed, with $386 million of Class A common stock repurchased [50] Q&A Session Summary Question: Can you elaborate on the progress from product and go-to-market changes? - Management highlighted strong Q1 performance and noted that upgrades contributed to outperformance, with Kokai adoption ahead of schedule [56][60] Question: What are the implications of Google's antitrust verdict for DSPs? - Management believes the verdict will create a fairer market, allowing the company to compete more effectively against reduced competition from Google [65][70] Question: How does the company view Q2 guidance amid uncertainty? - Management remains optimistic, citing strong underlying business fundamentals and the ability to assist clients in navigating challenges [72][75] Question: How is the competitive landscape evolving, particularly with Amazon? - Management views Amazon's focus on Prime Video as a limitation, asserting that the company’s CTV growth is outpacing Amazon's advertising growth [80][82] Question: What progress is being made with OpenPath and expectations for the upfront? - Management anticipates a stronger performance for programmatic advertising during the upfronts, with ongoing improvements in OpenPath [90][92]

Financial Data and Key Metrics Changes - Net sales for Q1 2025 were reported at $1,850 million, a decrease of 2.3% compared to $1,900 million in Q1 2024 [7] - Gross profit as a percentage of net sales increased to 56.5% from 54.1% in the previous year [8] - Operating income increased by 5.1% to $569.7 million from $542 million in Q1 2024 [9] - Net income for Q1 2025 was $443 million, slightly up from $442 million in Q1 2024 [10] - Diluted earnings per share increased by 7.4% to $0.45 from $0.42 in the previous year [10] Business Line Data and Key Metrics Changes - Sales of Monster energy drinks increased by 8.7%, while Reign sales decreased by 9.9% [13] - The Alcohol Brands segment saw a significant decline, with net sales down 38.1% to $34.7 million compared to the previous year [32] Market Data and Key Metrics Changes - In the U.S., the energy drink category grew by 10% year-over-year [5] - In EMEA, the energy drink category grew approximately 13.7% on an FX neutral basis [6] - In APAC, the category grew by 13.6% on an FX neutral basis [6] - In Latin America, the energy drink category grew by 15.7% on an FX neutral basis [6] - Monster's market share in the U.S. convenience and gas channel decreased from 37.1% to 36.4% [14][15] Company Strategy and Development Direction - The company is focused on expanding its product offerings and optimizing supply chains to enhance gross profit [8][9] - Plans for further innovation in the Monster Brewing segment are underway, with new products being launched in various markets [33][34] - The company is optimistic about long-term prospects in China and India, particularly with the rollout of the Predator brand [30][36] Management's Comments on Operating Environment and Future Outlook - Management noted that consumer demand remains strong, with positive trends in retail takeaway [39][40] - The company is optimistic about the energy drink category's growth, citing increasing household penetration and per capita consumption [39] - Management acknowledged challenges from foreign currency exchange rates and adverse weather impacting sales [7][10] Other Important Information - The company has approximately $500 million remaining for stock repurchase under its authorized program [36] - The juice plant at the AFF facility in Ireland is expected to be operational by mid-year 2025 [41] Q&A Session Summary Question: Impact of supply chain optimization on Q1 numbers - Management explained that Q1 was impacted by bottler distributor ordering patterns and distribution center closures, but April showed robust sales [47][48] Question: Macro impact on the energy category - Management indicated that the energy category remains healthy, with positive trends in both the U.S. and international markets [52][54] Question: Future gross margin expectations - Management expects that the second quarter margin will not be as high as Q1 due to rising costs from the Midwest premium [62] Question: Innovation pipeline and shipment timing - More innovation was rolled out in Q1 compared to Q2, with continued acceleration in distribution expected [66] Question: Pricing dynamics and market share satisfaction - Management stated that pricing decisions are based on market opportunities and emphasized the importance of regaining market share [72][73]

Financial Data and Key Metrics Changes - American Coastal Insurance reported a net income of $21.3 million, with core income at $20.7 million, a decrease of $3.7 million year-over-year due to increased policy acquisition costs [10] - The company achieved a combined ratio of 65%, aligning with its target, while the non-GAAP underlying combined ratio was 68.2% [10] - Cash and investments grew by 5.2% to $540.8 million, reflecting a strong liquidity position [11] - Stockholders' equity increased by 10.7% to $260.9 million, driven by first-quarter income, with book value per share rising to $5.4, a 10.4% increase from year-end 2024 [12] Business Line Data and Key Metrics Changes - Policies in force grew approximately 6% since year-end, with gross premiums written increasing by over 7% compared to the same period last year [4][5] - The underwriting environment for newer, well-maintained, low-rise, garden-style condos in Florida remains healthy and competitive, with the company passing on savings to policyholders through lower rates [5] Market Data and Key Metrics Changes - The Florida condominium market is facing challenges related to declining affordability and resale values, but these issues are not significantly impacting the company's business [5] - The company is focused on the inland Florida market, which is less affected by the current media attention on high-rise waterfront condos [5] Company Strategy and Development Direction - The company is increasing its catastrophe reinsurance program, with an estimated first event limit expected to rise approximately 16% year-over-year to about $1.35 billion [6] - The company is cautiously expanding into the apartment building market, averaging about 15 policies per month, with an average premium of over $100,000 [30][31] - The company aims to maintain a selective approach in the competitive apartment market while ensuring underwriting returns similar to those achieved in the condo sector [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong reserve position and the effectiveness of its growth strategy, despite increased policy acquisition costs [10][11] - The management team highlighted the importance of maintaining rate adequacy in a competitive market, particularly in areas like Tri County [21] - The company is optimistic about its growth initiatives for 2025, supported by a strong balance sheet and favorable underwriting conditions [12] Other Important Information - The company is increasing its internal quota share from 30% to 45%, which will enhance its balance sheet and capital flexibility [40] - A profit-sharing component was added to the Amrisk management fee agreement, which is expected to benefit both parties [41] Q&A Session Summary Question: Can you explain the rate trend chart on page nine? - The average account rate has been stable, with a decrease from record high levels, currently at 97 cents, which is considered healthy relative to historical premiums [20] Question: What has changed regarding the third event cover in your reinsurance program? - The reinstatement exposure has been reduced from approximately $13 million last year to about $5 million this year, indicating a significant improvement [24] Question: How is the apartment initiative progressing? - The company has averaged about 15 policies per month in the apartment initiative, with premiums aligning with targets, although the market is competitive [30][34] Question: What are the plans for quota sharing going forward? - The external quota share will be 15% from June 1, 2025, to May 31, 2026, with potential for further reductions depending on reinsurance costs and availability [38] Question: Can you discuss the changes to the Amrisk management fee? - The management fee has increased by 1% of premium written, with most of the increase passed on to producers to maintain revenue levels in a softening market [42]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 more than doubled year over year to $44.1 million from $21.5 million [6][13] - Adjusted net income increased to $17.3 million, representing a 158% increase compared to $6.7 million in the prior year [15] - Adjusted EBITDA also more than doubled to $24.5 million, with an adjusted EBITDA margin of 55.6% compared to 53.9% in the prior year [15] - GAAP net income attributable to stockholders was $4.6 million, compared to a GAAP net loss of $1.3 million in the prior year [15] Business Line Data and Key Metrics Changes - Life Solutions revenue was a key driver, with capital deployed increasing 128% to $124.9 million in Q1 2025 compared to $54.6 million in the prior year [13] - Asset management revenue for Q1 2025 was $7.8 million, marking the first full quarter of asset management fees from acquisitions [14] Market Data and Key Metrics Changes - New AUM inflows of $151 million were recorded, with approximately $123 million coming from expanded private fund offerings launched in late February [9][10] - The real assets ETF saw an increase in net new inflows of $44 million in the first quarter [10][72] Company Strategy and Development Direction - The company aims to solidify its position as a leader in alternative asset management and wealth management, focusing on uncorrelated assets [12] - A rebranding to Abacus Global Management reflects the company's evolution and expanded global market presence [10] - The company is committed to executing its growth strategy and expanding its brand recognition through a new advertising campaign [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating current market volatility and achieving full-year 2025 adjusted net income guidance of $70 million to $78 million, implying growth of 51% to 68% [6][16] - The macro environment remains uncertain, but the company believes it is well-positioned to capitalize on opportunities arising from market dislocations [9][12] Other Important Information - As of March 31, 2025, the company had cash and cash equivalents of $43.8 million and balance sheet policy assets of $448.1 million [9][16] - The company has purchased over $10 billion in face value of life insurance policies since February 2004 [10] Q&A Session Summary Question: Has there been an uptick in inquiries from policyholders since Liberation Day? - Management noted a noticeable increase in inquiries related to policyholder liquidity and investor demand for uncorrelated assets [20][21] Question: How does the company view the new repurchase authorization? - The company considers the repurchase option thoughtfully, evaluating stock valuation against return on equity from policies acquired [23][24] Question: Is the company fully deployed today? - Management confirmed that the capital deployment of nearly $125 million in Q1 was a record and indicated strong origination efforts [27][28] Question: What are the latest thoughts on the carrier buyback program? - Management reported ongoing activity in the carrier buyback program and noted increasing competition for assets [31][33] Question: Can you provide an update on technology solutions? - The technology solutions segment has nearly one million lives under management, with significant growth expected [41][42] Question: What is the mix of policy acquisitions? - Approximately 40% of policy flow was direct to consumer, 40% from financial advisors, and 20% from brokers [66] Question: What is the status of the AUM and advisor strategy? - The company reported significant inflows in both private funds and ETFs, with plans to grow the advisor strategy in the coming quarters [71][77]

Financial Data and Key Metrics Changes - The company reported a full year consolidated revenue growth of 16%, reaching a record level of $359 billion [6][42] - Adjusted earnings per diluted share was $33.05, exceeding expectations with a year-over-year growth of 20% [6][45] - Fourth quarter earnings per diluted share increased 64% to $10.12, driven by a lower effective tax rate and strong operational growth [35][36] Business Line Data and Key Metrics Changes - The U.S. Pharmaceutical segment revenues increased 21% to $83.2 billion, driven by increased prescription volumes and growth in specialty products [36] - The Prescription Technology Solutions segment saw revenues increase 13% to $1.3 billion, with operating profit rising 34% to $285 million [37] - The Medical Surgical Solutions segment revenues increased 1% to $2.9 billion, with operating profit up 15% to $285 million [39] Market Data and Key Metrics Changes - Revenues from GLP-1 medications in the fourth quarter were $10.9 billion, a 46% increase compared to the prior year [36] - The Canadian business, part of the international segment, experienced a 2% revenue decrease due to divestitures, but operating profit increased 9% [40][60] Company Strategy and Development Direction - The company is focusing on strategic acquisitions in oncology and biopharma services, including the acquisition of Prism Vision and Core Ventures [7][12] - A decision was announced to separate the Medical Surgical segment into an independent company to enhance strategic focus and capital deployment [20][29] - The company aims to leverage technology, automation, and AI to improve operational efficiencies and enhance financial profiles [9][63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to continue momentum and deliver strong results in fiscal 2026, anticipating revenue growth of 11% to 15% [46][66] - The company is closely monitoring the macroeconomic environment and potential impacts from policy changes, but remains optimistic about the healthcare industry's resilience [26][100] - Management emphasized the importance of community-based care and its role in managing healthcare costs and accessibility [72] Other Important Information - The company returned $3.5 billion to shareholders, including $3.1 billion through share repurchases [45] - Free cash flow for the fiscal year was $5.2 billion, driven by strong operational results [45][41] Q&A Session Summary Question: Impact of Medicare Part B on ASPs - Management indicated that there are currently no confirmed changes and emphasized the importance of community-based care in managing costs [69][72] Question: Tariff Impacts on Business - Management is monitoring the tariff landscape but does not anticipate a material impact on fiscal 2026 guidance [78][85] Question: Urgency in Capital Deployment for Biopharma Services - Management stated that the urgency for capital deployment remains consistent, driven by strategic alignment and financial discipline [90][93] Question: Long-term Pharma Growth Rate Guidance - Management noted that the increase in guidance reflects a stable environment for prescription utilization and successful capital deployment [97][101] Question: SG&A Efficiency Improvements - Management acknowledged a substantial decline in SG&A expenses year-over-year, attributing it to operational efficiencies [105]

Financial Data and Key Metrics Changes - The company reported a full year consolidated revenue growth of 16%, reaching a record level of $359 billion, with adjusted earnings per diluted share at $33.5, exceeding expectations and reflecting a year-over-year EPS growth of 20% [5][40][42] - Fourth quarter earnings per diluted share increased 64% to $10.12, driven by a lower effective tax rate and strong operational growth across the business [32][29] - Operating profit for the full year increased 15% to $5.6 billion, with significant contributions from the U.S. Pharmaceutical and Prescription Technology Solutions segments [41][42] Business Line Data and Key Metrics Changes - The U.S. Pharmaceutical segment saw revenues increase by 21% to $83.2 billion, driven by increased prescription volumes and growth in specialty product distribution [33][22] - The Prescription Technology Solutions segment reported a revenue increase of 13% to $1.3 billion, with operating profit rising 34% to $285 million, reflecting increased prescription transaction volumes [34][35] - The Medical Surgical Solutions segment experienced a 1% revenue increase to $2.9 billion, with operating profit up 15% to $285 million, benefiting from cost optimization initiatives [37][36] Market Data and Key Metrics Changes - The Canadian business, part of the international segment, reported revenues of $3.5 billion, a decrease of 2% due to the divestiture of certain businesses, but operating profit increased by 9% [38][24] - The company anticipates continued growth in the Canadian distribution business, partially offset by the impact of previous divestitures [58] Company Strategy and Development Direction - The company is focusing on strategic acquisitions in oncology and biopharma services, including the acquisition of a controlling interest in Prism Vision and Core Ventures, aimed at enhancing community-based care [6][12][49] - A strategic decision was made to separate the Medical Surgical segment into an independent company to enhance operational focus and capital deployment [19][27] - The company plans to continue investing in technology, automation, and AI to improve operational efficiencies and customer service [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to maintain momentum and deliver strong results in fiscal 2026, with anticipated revenue growth of 11% to 15% and operating profit growth of 8% to 12% [43][44] - The company remains committed to maximizing shareholder value through disciplined portfolio management and strategic capital deployment [27][62] Other Important Information - The company returned $3.5 billion to shareholders in fiscal 2025, including $3.1 billion through share repurchases [42] - Free cash flow for the fourth quarter was robust at $7.5 billion, driven by strong operating results [39] Q&A Session Summary Question: Impact of Medicare Part B on ASPs - Management indicated that there are currently no concrete announcements regarding Medicare Part B impacts, and any potential changes would likely face legal challenges [65][66] Question: Tariff Impacts on Business - Management is closely monitoring the tariff landscape and believes that current assessments have been incorporated into guidance, with no material impact anticipated on fiscal 2026 results [75][81] Question: Urgency in Capital Deployment for Biopharma Services - Management stated that the urgency for capital deployment remains consistent, driven by strategic alignment and financial discipline [85][88] Question: Long-term Pharma Growth Rate Guidance - Management noted that the increase in long-term guidance reflects a stable environment for prescription utilization and successful capital deployment in oncology and other specialties [92][96]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $99.9 million, more than doubled year over year, and was in line with guidance of $94 million to $104 million [9][26] - Non-GAAP gross margin was 30.7%, above the guidance range of 29% to 30.5%, and improved from 28.9% in Q4 2024 and 18.9% in Q1 2024 [29][30] - Non-GAAP net loss for Q1 was $0.9 million or $0.02 per share, compared to a loss of $12 million or $0.31 per share in Q1 2024 [31] Business Line Data and Key Metrics Changes - CATV segment revenue was $64.5 million, up more than six times year over year and increased 24% sequentially, driven by shipments of 1.8 GHz amplifiers [10][26] - Data center products revenue was $32 million, up 11% year over year but down 28% sequentially due to inventory digestion by a major customer [10][26] - Telecom segment revenue was $2.9 million, up 29% year over year but down 17% sequentially [28] Market Data and Key Metrics Changes - 60% of revenue came from CATV products, 32% from data center products, and 3% from FTTH, telecom, and other [26] - Demand for certain 100G products surged in Q1, potentially related to tariff concerns, but supply constraints limited production [20][27] Company Strategy and Development Direction - The company is focused on expanding production capacity for 800G and higher transceivers, with plans to reach approximately 40,000 transceivers per month by mid-2026 [14][15] - The company aims to minimize tariff impacts by assessing supply chain and manufacturing operations, with a commitment to onshore production [17][35] - The company is actively engaging with customers, particularly in the hyperscale data center market, to expand revenue opportunities [19][68] Management's Comments on Operating Environment and Future Outlook - Management noted strong demand in the CATV market and positive long-term growth trends in both CATV and data center markets [12][13] - Tariffs had no material impact on Q1 financials, and management does not expect significant impact in Q2 based on current information [13] - The company expects Q2 revenue to be between $100 million and $110 million, with a modest sequential decrease in CATV revenue and an increase in data center revenue [36] Other Important Information - The company ended Q1 with $66.8 million in cash and equivalents, down from $79.1 million at the end of Q4 2024 [32] - Total debt, excluding convertible debt, was $46.1 million, slightly up from $46 million in the previous quarter [32] - The company raised $98 million net under a new at-the-market offering to fund investments in production and R&D [34] Q&A Session Summary Question: Understanding channel inventory for cable TV products - The company has good knowledge of inventory levels through reports from MSOs and channel partners, and there is an intentional inventory buildup due to tariff situations [38][40] Question: Progress with 800G products - The company expects to ramp up production capacity to about 100,000 pieces per month by the end of the year, with a significant revenue contribution anticipated in the second half [44][45] Question: Manufacturing in China - The company is not manufacturing any products with a country of origin in China for tariff purposes, although some operations occur there [46] Question: Retooling to Motorola style amplifiers - The company is shifting production to Motorola style amplifiers, expecting to have significant inventory of both products by June [54][55] Question: Long-term market for 800G - The market for 800G is expected to grow significantly, with the company positioned to capture a substantial share, particularly with major customers like Amazon [57][76] Question: CapEx needs and funding - The company has completed a significant ATM offering and is exploring other funding options, but remains confident in achieving profitability this year [60][61]